Cancer Family
Epithelial Neoplasm
CI-CAN-00000016Explore in graph →
Non-malignant7,533 active trials118 approved drugs1,153 evidence items
- NCIt
- C3709
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000016Explore in graph →
Clinical trials
26,893 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04190498 | Sleep Apnoea Syndrome and Hepatocellular Carcinoma(ECHAPS) | withdrawn | — | 0 | University Hospital, GrenobleOTHER | 1 | May 24, 2022 | clinicaltrials |
| NCT05041751 | Myofascial Release or Trigger Point Injections for the Reduction of Post-Mastectomy Pain Syndrome | withdrawn | N/A | 0 | M.D. Anderson Cancer CenterOTHER | 0 | May 17, 2022 | clinicaltrials |
| NCT03839472 | Continuous Bladder Irrigation Following Transurethral Resection of Bladder Tumors | withdrawn | N/A | 0 | Case Comprehensive Cancer CenterOTHER | 1 | May 11, 2022 | clinicaltrials |
| NCT05104905 | A Phase I/II Open Label Single Centre Trial to Assess the Safety, Tolerability and Efficacy of Single Dose Neoadjuvant Anti-CLEVER-1 Antibody Bexmarilimab in Localised Renal Cell and Colon Carcinoma(RENACOL) | withdrawn | Phase 1 / Phase 2 | 0 | Faron Pharmaceuticals LtdINDUSTRY | 1 | May 11, 2022 | clinicaltrials |
| NCT04465734 | A Clinical Study to Compare the Efficacy and Safety of HLX10 in Combination With HLX04 Versus Sorafenib as the First-line Treatment in Patients With Locally Advanced or Metastatic HCC | withdrawn | Phase 3 | 0 | Shanghai Henlius BiotechINDUSTRY | 1 | May 5, 2022 | clinicaltrials |
| NCT04331717 | Bariatric Arterial Embolization for Men Starting Hormones for Prostate Cancer(BASH-PC) | withdrawn | Phase 2 | 0 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | May 2, 2022 | clinicaltrials |
| NCT04841538 | A Study of ES101 (PD-L1x4-1BB Bispecific Antibody) in Patients With Advanced Malignant Thoracic Tumors | withdrawn | Phase 1 / Phase 2 | 0 | Elpiscience Biopharma, Ltd.INDUSTRY | 0 | Apr 29, 2022 | clinicaltrials |
| NCT02850874 | HIPEC as Neoadjuvant Treatment for Resectable Pancreatic Adenocarcinoma | withdrawn | Phase 2 | 0 | Wake Forest University Health SciencesOTHER | 1 | Apr 27, 2022 | clinicaltrials |
| NCT04625543 | Neoadjuvant Immunotherapy to ESCC | withdrawn | Phase 2 | 0 | Qilu Hospital of Shandong UniversityOTHER | 1 | Apr 26, 2022 | clinicaltrials |
| NCT04003025 | Body Composition and Prognosis in Head and Neck Squamous Cell Carcinoma (HNSCC)(HNCAX01) | withdrawn | — | 0 | Instituto do Cancer do Estado de São PauloOTHER | 1 | Apr 20, 2022 | clinicaltrials |
| NCT04480190 | Neoadjuvant Therapy in Biliary Adenocarcinoma | withdrawn | Phase 1 | 0 | Jordan KharofaOTHER | 1 | Apr 20, 2022 | clinicaltrials |
| NCT04795596 | Secondary Cytoreductive Surgery in Platinum-resistant Recurrent Ovarian Cancers | withdrawn | Phase 2 / Phase 3 | 0 | Menoufia UniversityOTHER | 1 | Apr 15, 2022 | clinicaltrials |
| NCT05234606 | A Safety and Preliminary Efficacy Study of SBT6290 Alone and in Combination With PD-(L)1 Inhibitors in Select Advanced Solid Tumors | withdrawn | Phase 1 / Phase 2 | 0 | Silverback TherapeuticsINDUSTRY | 0 | Apr 12, 2022 | clinicaltrials |
| NCT03682744 | CAR-T Intraperitoneal Infusions for CEA-Expressing Adenocarcinoma Peritoneal Metastases or Malignant Ascites (IPC) | withdrawn | Phase 1 | 0 | Sorrento Therapeutics, Inc.INDUSTRY | 1 | Apr 6, 2022 | clinicaltrials |
| NCT05019677 | GP Chemotherapy in Combination With Tislelizumab and Ociperlimab as First-line Treatment in Advanced BTC | withdrawn | Phase 2 | 0 | Fudan UniversityOTHER | 1 | Apr 4, 2022 | clinicaltrials |
| NCT04266470 | Monitoring Blood Flow and Metabolic Activity in Malignant Tissue of Head and Neck Region | withdrawn | N/A | 0 | Wake Forest University Health SciencesOTHER | 0 | Mar 29, 2022 | clinicaltrials |
| NCT04754815 | Study of Pembrolizumab With Single Agent Chemotherapy in Elderly Patients With Advanced NSCLC(HFHS 21-01) | withdrawn | Phase 2 | 0 | Shirish GadgeelOTHER | 0 | Mar 29, 2022 | clinicaltrials |
| NCT04231929 | BioPearl™ Microspheres Loaded With Doxorubicin: Prospective, Single Arm, Multi-centre Post-market Follow-up Study.(BIOPEARL-FIRST) | withdrawn | N/A | 0 | Terumo Europe N.V.INDUSTRY | 1 | Mar 28, 2022 | clinicaltrials |
| NCT03770299 | An Investigational Immuno-therapy Study of Nivolumab Given After Surgery in Non-Small Cell Lung Cancer (NSCLC) Participants With Minimal Residual Disease(CheckMate 9TN) | withdrawn | Phase 2 | 0 | Bristol-Myers SquibbINDUSTRY | 0 | Mar 24, 2022 | clinicaltrials |
| NCT02662634 | A Safety and Feasibility Study of AGS-003-LNG for the Treatment of Stage 3 Non Small Cell Lung Cancer | withdrawn | Phase 2 | 0 | GU Research Network, LLCOTHER | 1 | Mar 18, 2022 | clinicaltrials |
| NCT03745690 | Near-Infrared Image Guided Surgical Resection With Indocyanine Green in Treating Patients With Head and Neck Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Mar 17, 2022 | clinicaltrials |
| NCT02427581 | Safety and Immunogenicity of a Personalized Synthetic Long Peptide Breast Cancer Vaccine Strategy in Patients With Persistent Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy | withdrawn | Phase 1 | 0 | Washington University School of MedicineOTHER | 0 | Mar 10, 2022 | clinicaltrials |
| NCT03592407 | Epacadostat and Pembrolizumab Before Surgery in Treating Participants With Stage II-III Esophageal or Gastroesophageal Cancer | withdrawn | Phase 2 | 0 | City of Hope Medical CenterOTHER | 1 | Mar 8, 2022 | clinicaltrials |
| NCT04061590 | Pembrolizumab With or Without Chemotherapy Before Surgery in Treating Patients With Stage I-IIIA Non-Small Cell Lung Cancer | withdrawn | Phase 2 | 0 | University of California, San FranciscoOTHER | 1 | Mar 4, 2022 | clinicaltrials |
| NCT04470674 | Study of Durvalumab or Durvalumab Plus Chemotherapy in Kras Mutation Positive and PD-L1 High (≥ 50%) NSCLC Patients | withdrawn | Phase 2 | 0 | Shirish M GadgeelOTHER | 1 | Mar 3, 2022 | clinicaltrials |
| NCT04611139 | Pilot Trial of SP-2577 Plus Pembrolizumab in Select Gynecologic Cancers | withdrawn | Phase 1 | 0 | HonorHealth Research InstituteOTHER | 1 | Mar 2, 2022 | clinicaltrials |
| NCT04179110 | Study of Pembrolizumab and Ramucirumab in Pts With Progressive TCC After Treatment With an Immune Checkpoint Inhibitor | withdrawn | Phase 2 | 0 | Yale UniversityOTHER | 1 | Feb 22, 2022 | clinicaltrials |
| NCT04832438 | 9-ING-41 Plus Carboplatin in Patients With Advanced, Metastatic Salivary Gland Carcinoma | withdrawn | Phase 2 | 0 | Actuate Therapeutics Inc.INDUSTRY | 1 | Feb 22, 2022 | clinicaltrials |
| NCT03035630 | Sunitinib Followed by Avelumab or the Reverse for Metastatic Renal Cell Carcinoma | withdrawn | Phase 2 | 0 | Guru SonpavdeOTHER | 1 | Feb 15, 2022 | clinicaltrials |
| NCT04119830 | Rintatolimod and Pembrolizumab for the Treatment of Refractory Metastatic or Unresectable Colorectal Cancer | withdrawn | Phase 2 | 0 | Roswell Park Cancer InstituteOTHER | 1 | Feb 8, 2022 | clinicaltrials |
| NCT04129320 | Enoblituzumab Plus MGA012 or MGD013 in Squamous Cell Carcinoma of the Head and Neck | withdrawn | Phase 2 / Phase 3 | 0 | MacroGenicsINDUSTRY | 0 | Feb 8, 2022 | clinicaltrials |
| NCT05008510 | P2 Clinical Efficacy & Safety Study of V-111 Monotherapy & Sacituzumab Govitecan-hziy/V-111 Combo Therapy for mTNBC .(VERU-111) | withdrawn | Phase 2 | 0 | Veru Inc.INDUSTRY | 0 | Feb 8, 2022 | clinicaltrials |
| NCT05181865 | Phase 1/2a Study to Evaluate FL-301 in Patients With Advanced Solid Tumors | withdrawn | Phase 1 / Phase 2 | 0 | Flame BiosciencesINDUSTRY | 0 | Feb 7, 2022 | clinicaltrials |
| NCT04186988 | [18F]-AraG for the Detection of T-Cell Activation in Advanced Non-small Cell Lung Cancer Patients Undergoing PD-1/PD-L1-Directed Therapy | withdrawn | Early Phase 1 | 0 | University of California, DavisOTHER | 0 | Feb 1, 2022 | clinicaltrials |
| NCT03908255 | Branched-chain Amino Acid Supplementation for Hepatocellular Carcinoma(BCAA in HCC) | withdrawn | Phase 2 | 0 | Louisiana State University Health Sciences Center in New OrleansOTHER | 1 | Jan 28, 2022 | clinicaltrials |
| NCT05099952 | Sleep and Circadian Rhythm Study in Head and Neck Cancer Patients | withdrawn | N/A | 0 | Roswell Park Cancer InstituteOTHER | 1 | Jan 12, 2022 | clinicaltrials |
| NCT04758949 | FL-101 in Surgically Resectable Non-Small Cell Lung Cancer | withdrawn | Phase 2 | 0 | Flame BiosciencesINDUSTRY | 0 | Jan 11, 2022 | clinicaltrials |
| NCT03319316 | Combination of Durvalumab and Tremelimumab as Maintenance Treatment in Patients With Non Squamous and Squamous (NSCLC)(SOLUTION) | withdrawn | Phase 2 | 0 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 0 | Jan 10, 2022 | clinicaltrials |
| NCT04874831 | Domatinostat in Combination With Avelumab in Patients With Treatment-naïve Metastatic Merkel Cell Carcinoma (MERKLIN 1) | withdrawn | Phase 2 | 0 | 4SC AGINDUSTRY | 0 | Nov 18, 2021 | clinicaltrials |
| NCT04778566 | Evaluating the Cologuard Test for Use in Lynch Syndrome | withdrawn | — | 0 | Geisinger ClinicOTHER | 1 | Nov 17, 2021 | clinicaltrials |
| NCT04499352 | A Study to Test BI 754091 Alone or in Combination With BI 836880 in People Who Have Advanced Anal Cancer | withdrawn | Phase 2 | 0 | Boehringer IngelheimINDUSTRY | 1 | Nov 15, 2021 | clinicaltrials |
| NCT04418895 | Neoadjuvant Therapy for Localized Rectal Adenocarcinoma | withdrawn | Phase 2 | 0 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Nov 10, 2021 | clinicaltrials |
| NCT03231475 | Phase I Study of SPH1188-11 in NSCLC(SPH1188-11) | withdrawn | Phase 1 | 0 | Shanghai Pharmaceuticals Holding Co., LtdINDUSTRY | 1 | Nov 8, 2021 | clinicaltrials |
| NCT05007769 | Ramucirumab, Atezolizumab and N-803 After Progression on Any Immune Checkpoint Blocker in NSCLC(RAN) | withdrawn | Phase 2 | 0 | Washington University School of MedicineOTHER | 0 | Nov 5, 2021 | clinicaltrials |
| NCT04262869 | Platinum-Based Chemotherapy and Durvalumab for the Treatment of Stage IIIB or IV Non-small Cell Lung Cancer | withdrawn | Phase 2 | 0 | Emory UniversityOTHER | 0 | Oct 27, 2021 | clinicaltrials |
| NCT04831827 | Promoting Equity for Cancer Screening and Follow-up | withdrawn | N/A | 0 | Mayo ClinicOTHER | 1 | Oct 27, 2021 | clinicaltrials |
| NCT05001360 | Study of FMT Combined With Nivolumab in Gastric Cancer | withdrawn | N/A | 0 | Fujian Cancer HospitalOTHER_GOV | 1 | Oct 27, 2021 | clinicaltrials |
| NCT03634150 | Safety and Efficacy of IV Nerofe™ Followed by Doxorubicin, In Metastatic Ovarian Cancer and Triple Negative Breast Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Immune System Key LtdINDUSTRY | 1 | Oct 26, 2021 | clinicaltrials |
| NCT04585724 | Stereotactic Radiosurgery With Abemaciclib, Ribociclib, or Palbociclib in Treating Patients With Hormone Receptor Positive Breast Cancer With Brain Metastases | withdrawn | Phase 1 | 0 | Emory UniversityOTHER | 0 | Oct 18, 2021 | clinicaltrials |
| NCT02289807 | Concurrent Chemotherapy in Intermediate Risk Patients Treated With Intensity-modulated Radiotherapy | withdrawn | N/A | 0 | Sun Yat-sen UniversityOTHER | 1 | Oct 15, 2021 | clinicaltrials |
Data updated 24 days agoSource updated May 24, 2022source: clinicaltrials